Not the writer, the first man to undertake the Covid gene therapy.
I closed the case in this post’s cover gif animation. All I have to add is a few references:
We're sorry to hear of the death of Coventry Labour stalwart Bill Shakespeare. Bill made global headlines as 1st first man to have Covid vaccine. His decades of service to the party were recently recognised by @Keir_Starmer. Our thoughts are with Joy and Bill's family & friends. pic.twitter.com/ANCTeGFYEs
“Experimental” means we are not done finding out what relates to it, how and when.
SILVIEW.media
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
I’m trying to advance the discussion, but apparently most are still stuck at “these are not even vaccines”. Yeah, we knew that the moment we visited a manufacturer’s website, which is among the first reasonable things to do. I hope this will help closing that debate and will ease stepping further down the rabbit hole. Watch how many will find out these things from me rather than from the original source!
Without mRNA, your genetic code would never get used by your body. Proteins would never get made. And your body wouldn’t – actually couldn’t – perform its functions. Messenger ribonucleuc acid, or mRNA for short, plays a vital role in human biology, specifically in a process known as protein synthesis. mRNA is a single-stranded molecule that carries genetic code from DNA in a cell’s nucleus to ribosomes, the cell’s protein-making machinery.
Recognizing the broad potential of mRNA science, we set out to create an mRNA technology platform that functions very much like an operating system on a computer. It is designed so that it can plug and play interchangeably with different programs. In our case, the “program” or “app” is our mRNA drug – the unique mRNA sequence that codes for a protein.
We have a dedicated team of several hundred scientists and engineers solely focused on advancing Moderna’s platform technology. They are organized around key disciplines and work in an integrated fashion to advance knowledge surrounding mRNA science and solve for challenges that are unique to mRNA drug development. Some of these disciplines include mRNA biology, chemistry, formulation & delivery, bioinformatics and protein engineering.
Our mRNA Medicines – The ‘Software of Life’
When we have a concept for a new mRNA medicine and begin research, fundamental components are already in place.
Generally, the only thing that changes from one potential mRNA medicine to another is the coding region – the actual genetic code that instructs ribosomes to make protein. Utilizing these instruction sets gives our investigational mRNA medicines a software-like quality. We also have the ability to combine different mRNA sequences encoding for different proteins in a single mRNA investigational medicine.
We are leveraging the flexibility afforded by our platform and the fundamental role mRNA plays in protein synthesis to pursue mRNA medicines for a broad spectrum of diseases.
Within a given modality, the base components are generally identical across development candidates – formulation, 5’ region and 3’ region. Only the coding region varies based on the protein/s the potential medicine is directing cells to produce.
Learn how our Research Engine and Early Development Engine are enabling us to fully maximize the promise of mRNA to meaningfully improve how medicines are discovered, developed and manufactured.
‘Life is just a flow of information. And we’re interfering with it”
Overcoming Key Challenges
Using mRNA to create medicines is a complex undertaking and requires overcoming novel scientific and technical challenges. We need to get the mRNA into the targeted tissue and cells while evading the immune system. If the immune system is triggered, the resultant response may limit protein production and, thus, limit the therapeutic benefit of mRNA medicines. We also need ribosomes to think the mRNA was produced naturally, so they can accurately read the instructions to produce the right protein. And we need to ensure the cells express enough of the protein to have the desired therapeutic effect.
Our multidisciplinary platform teams work together closely to address these scientific and technical challenges. This intensive cross-functional collaboration has enabled us to advance key aspects of our platform and make significant strides to deliver mRNA medicines for patients.
Our mRNA RESEARCH ENGINE™ services enable us to advance new product ideas into development candidates via our drug discovery efforts, and includes infrastructure to enable rapid supply of thousands of preclinical mRNAs for research involving in vitro and in vivo experiments in order to accelerate programs from idea to development candidate designation.
mRNA Design Studio™ – Digital Design and Ordering of mRNA for Research
Our mRNA Design Studio enables rapid design of multiple mRNAs.
As our scientists create new mRNA concepts, they can design mRNAs for research and testing, within days, using our proprietary systems. As the Digital Biotech Company™, we utilize the software-like property of mRNA in our proprietary, web-based mRNA Design Studio. Our scientists request mRNAs for a specific protein, and the protein target is automatically converted to an initial optimized mRNA sequence. Using our Sequence Designer module, they can tailor entire mRNAs from the 5’-UTR to the coding region to the 3’-UTR based on our ever-improving proprietary learnings. The mRNA sequence is then further optimized using our proprietary bioinformatics algorithms. Our digital ordering then ensures rapid and accurate transmission of sequences to our modular synthesis robotics.
Our proprietary in-house digital application suite contains a Sequence Designer module to tailor an entire mRNA, with ever-improving rule sets that contain our accumulated learning about mRNA design. Drug Design Studio utilizes cloud-based computational capacity to run various algorithms we have developed to design each mRNA sequence. The utility of cloud-based capacity allows us to provide flexible computational capacity on demand, allowing the Research Engine to power parallel intake and design of multiple mRNA sequences.
Moderna’s Research Engine
Our Research Engine combines proprietary digital drug design tools and a highly automated production facility to enable Moderna and our strategic collaborators to move mRNA medicines swiftly through the research stage, from idea to development candidate nomination.
Scientists can begin by selecting any protein in the human proteome to be further engineered, including antibodies, or they can design novel proteins like traps, fusion proteins, or completely novel scaffolds and sequences. All can be designed to explore previously undruggable pathways.
The Drug Design Studio integrates with Moderna’s automation platforms – directing orders through each phase of mRNA synthesis. Once the order is placed, Moderna’s high-throughput mRNA pre-clinical production facility manages the manufacturing of mRNA constructs and delivers them in just weeks.
PS: Some people wonder why the vids above are available on their website but unlisted on their Youtube. It’s because they know you won’t look for them on their site, mostly potential partners will.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
We gave up on our profit shares from masks, if you want to help us, please use the donation button! We think frequent mask use, even short term use can be bad for you, but if you have no way around them, at least send a message of consciousness. Get it here!
I have a feeling most of the World will be surprised to find out it was enrolled without informed consent in a vaccine trial
Australian Health Minister Greg Hunt has spilled the beans recently on live TV, for millions to hear, but when the mind is blind, you need to wait until the clip reaches some Romanian researcher stranded in Morocco, or something. Luckily the Internet can make this possible and here we are, maybe more people “click” now.
Normally, I avoid posting this type of sound-bites here without a consistent context, but I think this one deserves an exceptions because it speaks volumes in seconds and doesn’t really require much more context than I’ve already added.
Worth mentioning that, according to the ethical principles of clinical research, trial subjects for experimental medical treatments cannot be blood or organ donors.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Sometimes my memes are 3D. And you can own them. Or send them to someone. You can even eat some of them. CLICK HERE
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
“In the early nineties, pioneering steps were taken in the use of mRNA as a therapeutic tool for vaccination. In the following decades, an improved understanding of the mRNA pharmacology, together with novel insights in immunology have positioned mRNA-based technologies as next-generation vaccines.”
Like teenagers the world over, Nobel Prize-winning scientist Ralph Steinman had absolutely no idea what he wanted to do when he grew up.
In a 2009 essay, the Canadian-born immunologist and cell biologist described his early school career as unfocused, only landing on an interest in biology and medicine while taking “almost every other course” at McGill University in Montreal while on scholarship as an undergraduate.
This latent interest eventually led him to Harvard Medical School, where he earned his M.D. (also on scholarship), and an internship and residency at Massachusetts General Hospital. In 1970, the young Steinman joined the Laboratory of Cellular Physiology and Immunology at Rockefeller University in New York City as a postdoctoral fellow under cell biologist and immunologist Zanvil A. Cohn. Steinman wanted to know what triggers the body’s immune system to kick into gear to initiate a response, a question few scientists at the time were asking.
Just three years later, while working with cells from the spleens of mice, Steinman and Cohn made the discovery that would shape Steinman’s future: the identification and role of a particular type of white blood cell that sets into motion and controls the body’s immune system. They termed these cells dendritic cells, after the branching, tree-like shape the cells can form.
By identifying this chief component that initiates and regulates an immune response, Steinman had discovered why, when, and how the body’s immune system reacts the way that it does, especially in the face of foreign pathogens. He’d discovered what amounted to the boss cell that kicks off immune reactions and tells other cells what to do and what not to do. Dendritic cells also play a role in autoimmune diseases, inflammation, allergies, and transplant rejections.
This discovery would revolutionize immunotherapy and eventually launch the new field of dendritic cell biology. But at the time, Steinman’s discovery was generally disregarded. Dendritic cells were considered little more than an obscure anomaly by much of the scientific community. To top it off, the cells were difficult to isolate, and low in frequency and abundance to boot. It would take more than 20 years and Steinman’s development of a new method to generate large numbers of dendritic cells for experimental use for the scientific community to finally verify and accept his theories.
His chances for surviving another year were estimated at less than five percent.
Steinman was especially interested in clinical applications for dendritic cells, dedicating much of his career toward the development of new medical therapies and treatments based on his research. His discovery led to the first therapeutic cancer vaccine in 1973, a dendritic cell-based immunotherapy for the treatment of prostate cancer. Other potential immunotherapies that have resulted include cancer and transplantation treatments and vaccines for HIV, malaria, tuberculosis, and the Epstein-Barr virus, some of which have reached clinical trials.
Steinman’s desire to see his research put into practical medical application cannot be overstated. Despite his gentle, almost grandfatherly way of speaking, he often expressed frustration at the slow speed at which experimental therapies escaped the confines of the lab and its theoretical animal and data models to reach actual patients. This impatience took on a new sense of urgency in 2007 when Steinman was diagnosed with Stage 4 (advanced) pancreatic cancer. By the time of his diagnosis, the cancer had already advanced beyond the pancreas and spread to Steinman’s lymph nodes. His chances for surviving another year were estimated at less than five percent.
So, Steinman went to work. In response to his illness, he designed and coordinated a single-case medical study with himself as the sole subject.
In addition to undergoing conventional surgery and chemotherapy, Steinman reached out to the international network of researchers in industry and academia he’d built over his decades-long career. Banding together for this common cause, he and his colleagues developed a variety of personalized cancer treatments, many based on his design and research, including vaccines developed from Steinman’s own tumor cells.
“With ten million persons afflicted each year, no one is entirely immune to cancer and its devastating effects on individuals and families. But recent advances in the development of cancer vaccines—either as therapeutic agents or as preventative measures—are hopeful indicators of progress in this field. This volume comprises invited chapters from world-renowned researchers and clinicians that shed light on recent steps forward in immunotherapeutic and preventive approaches for future cancer vaccines.” – Blackwell Publishing
A close-up look at a dendritic cell, the boss cell that kicks off immune reactions and tells other cells what to do and what not to do.
Despite his general impatience with the speed of the traditional scientific process, Steinman insisted on conducting his personal trial according to established protocols, filing mounds of paperwork with official channels and seeking appropriate permissions for untested therapies just like any other trial. Although his personalized experiment was not controlled, he wanted it well-organized and well-documented so his treatment attempts might not only find a cure for himself but also gather knowledge that could be used to benefit others.
This adherence to protocol, however, became a source of frustration for some of Steinman’s colleagues. Steinman, for example, refused combined therapies that failed to get regulatory approval, even though he and many of his colleagues felt the combined approach had a higher likelihood of success. He also initially refused to undergo multiple treatments at once because doing so would confuse the data being collected. With time of the essence, colleagues had to argue with Steinman to get him to prioritize the possibility of his health and longevity over proper protocol and clean experimental results. All told, Steinman underwent as many as eight experimental therapies, in addition to surgery and chemotherapy, to combat his disease.
Four and a half years after his cancer diagnosis, he died just three days before the Nobel Prize announcement
During his long career, he received numerous awards and honors, including the prestigious Lasker Award (sometimes referred to as the American Nobel) in 2007. While in the midst of his illness and self-experimentation, he was also nominated for the 2011 Nobel Prize in Physiology or Medicine for his discovery of the dendritic cell and subsequent contributions to immunology research and medicine.
Steinman joked often about surviving long enough to witness the awards announcement, and as late as a week before, the possibility seemed likely. But on September 30, 2011, four and a half years after his cancer diagnosis, he died just three days before the Nobel Prize announcement. He was 68 years old.
Nobel Prize rules generally prohibit the awarding of a prize posthumously, but given the unusual circumstances and unfortunate timing of events, the Nobel Committee ruled to allow the honor to stand. Steinman shares the prize with American immunologist Bruce A. Beutler and French biologist Jules A. Hoffman, also for their work in the area of immunity research.
Although no one can be sure of the efficacy of the dendritic cell-based immunotherapies Steinman underwent or which one(s) might have helped, the Nobel Laureate lived more than four times longer than expected. His decades of work have contributed to clinical therapies for cancer and infectious diseases that will benefit patients for generations to come. And despite those early years of unfocused study, even his self-experimentation laid the groundwork for future treatments, including an immunotherapy against pancreatic cancer based on data gathered during Steinman’s final experiment. – Folks Magazine
Ralph Steinman died days before it was announced that he was to share the Nobel Prize for Medicine. His work had been part of an unorthodox experiment to save his life, wrote Politico journalist Brett Norman, quoted by BBC, 2011.
When Ralph Steinman learned he had pancreatic cancer, the dogged immunologist put his life’s work to the test.
He launched a life-and-death experiment in the most personal of personalised medicine.
By unlucky coincidence, he had been diagnosed with a disease that might benefit from the therapies he had spent his life researching.
Usually, medical research proceeds at a glacial, thorough pace: cell studies lead to studies in small animals which lead to studies in larger animals, which eventually lead to small, highly-selective clinical trials in humans. But Steinman didn’t have that kind of time.
He did, however, have access to world class facilities, cutting-edge technology, and some of the world’s most brilliant medical minds, thanks to his position as a researcher at Rockefeller University.
So Steinman decided to make his own body the ultimate experiment.
He had removed a piece of the tumour that would eventually kill him. He then trained his immune cells to track down any hint of the tumour that might have escaped the surgery, like putting hounds on a scent.
On Friday, four-and-a-half years after he was diagnosed with a disease that kills the vast majority of its victims in less than one, that experiment came to an end.
Steinman died at the end of a week in which he continued his work in the lab. It was a testament to the undying optimism of the scientific enterprise, to the unrelenting man, and to the limits of both.
An open secret
I joined Rockefeller as a science writer to chronicle the work of its researchers – Steinman included – about halfway through one of his experiments on himself.
His experiment was an open secret on campus, registered with the hospital and aided by a long-time friend and staff physician. The sense of hope was palpable, bound up in respect for the man but also something broader.
Could the painstakingly incremental research that seemed to have so much potential on lab animals this once grant a reprieve from certain death?
Of course everyone was rooting for him, and I had a special interest. Toward the end of 1999, my father had a stomach complaint. Over a few months, the initial diagnosis of an ulcer morphed into a death sentence: inoperable, metastatic cancer of the pancreas.
Pancreatic cancer is often known as the “silent killer” because it usually doesn’t produce truly scary symptoms until it has spread beyond repair. After chemotherapy, my dad bounced back for a few months, but the cancer inevitably did, too. He died at home in the early fall of 2000.
Could Steinman beat it?
I hoped so. The work had promise.
“In the last few years of his life, Dr. Ralph Steinman made himself into an extraordinary human lab experiment, testing a series of unproven therapies – including some he helped to create – as he waged a very personal battle with pancreatic cancer.”
In 1973, along with his mentor, Zanvil Cohn, Steinman published the discovery of a new class of cell in the immune system – the dendritic cell. Like many new discoveries, his faced a deeply sceptical reception.
The experiments couldn’t be immediately reproduced, but Steinman was convinced of his discovery. He fought for a decade before immunologists began to broadly recognise the central importance of those cells to their field.
In the past 20 years, the study of dendritic cells has spread to hundreds of labs all over the world. Researchers are exploring how they might be harnessed to fight cancer, HIV and transplant rejection, among other major medical problems.
Dendritic cells are the “sentinel cells” of the mammalian immune system. Named after the Greek word for tree, they develop distinctive probing branches when activated, sweeping their environment in search of unwelcome things – like bacteria, viruses, tumours.
When dendritic cells encounter something they don’t like, they take a physical marker of the invader, called an antigen, and present it to B and T cells, the defenders of the body’ s immune system. Those cells then adapt weapons to identify and destroy the interlopers.
Steinman bet that if he could train his dendritic cells to recognise and tag his cancer, they would be able to convince the T and B cells to do the rest.
Dream deferred
There was no good reason to expect that Steinman could fashion a cure for one of the world’s most vicious cancers in time to save his own life. But it was easy to think it was at least possible. The made-for-Hollywood story of the renegade scientist who fights the establishment to prove his discovery, and then uses it to cure himself, was powerful enough to compel hope.
Unfortunately, the dendritic cell-based treatments didn’t work – at least not well enough.
Training Steinman’s dendritic cells to the tumour did generate a “vigorous immune response to mesothelin, a tumour specific antigen,” said Dr. Sarah Schlesigner, a longtime colleague of Steinman’s who ran the trial.
In other words, while there were significant side effects, the therapy seemed to enable him to work much longer than he otherwise would have. Month after month, he remained at the University, continuing his work.
He survived much longer than expected, and continued his research until the end.
Over time, it wasn’t enough.
At least, not enough to save him.
But the research he pioneered continues – and the scientists who continue his work have an extraordinary example to follow. – BBC, 2011
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Sometimes my memes are 3D. And you can own them. Or send them to someone. You can even eat some of them. CLICK HERE
Our nano-grand-jury has settled: best scamdemic videos of 2021 so far, and for a while, are:
YOUTUBE BANNED OUR VIDEO IN LIKE 30 MIN, BUT WE ALREADY HAVE IT ON ODYSEE / BITCHUTE / BRIGHTEON
Seems like Youtube hurried to prove our point lmao
UPDATE: WE’RE FIRING BACK AT YOUTUBE CENSORSHIP WITH THEIR WEAPONS, OUR STRATEGY AND BACK-UP CHANNEL. FOR THIS TO WORK, WE VERY MUCH NEED TO SEE SOME LOVE FOR THIS ARTICLE AND THE VIDEO BELOW, WHICH HAS TO BECOME POPULAR ON YOUTUBE, NOT ELSEWHERE, WE NEED TO SCORE ON THEIR FIELD IF WE ARE TO WIN THE CHAMPIONSHIP! THANK YOU!
THE PART 2 OF OUR EULOGY SURVIVED THE YOUTUBE SCIENCE SLAUGHTER
Amen
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Anyone who has any remnants of humanity inside has asked this question. One answer is no secret to anyone: poor countries. But that’s not always the case, and this is where it gets darker.
The ethics of deliberately infecting volunteers with Covid-19 to test vaccines are a complicated issue only if you value something more than human life, which is actually common, but not the case here. So I’m not making a secret that everything I know and feel made me conclude long ago that most medical tests that occurred on humans were abominations permitted only by a massive lack of empathy / humanity and usually driven by financial incentives. Everything that followed after that was but a confirmation. Point being: I’m long over that debate, there is absolutely no essential difference between the Bayer labs in Auschwitz and the Pfizer Labs in London (or wherever). And I know a large slice of society, if not the majority, still has major moral, rational and ethical concerns about this, luckily, and it can’t be that easy to find these kids without leveraging finances on poorest people, and even then… Proof to that, Moderna has just publicly admitted it has big difficulties in finding 3000 kids, and I hope they never sort it out. So much so that They appealed to all their presstitutes to make a roll call for them. Funnily, only days after Moderna’s appeal, CBS lies that they were having “more than enough volunteers, so basically these two messages are now still being propagated simultaneously: “Last fall, the Clinical Research Institute sent out letters to pediatricians’ offices and posted on Facebook looking for volunteers in the 12-year-old to 17-year-old age group. Though the study will run for 13 months, the researchers have more than enough volunteers for this trial.” – CBS
Since you can’t expect anyone involved to be honest and open about it, based on their past and present performance, and they’re not, where to find the answer? There’s about 50 vaccines being trialed right now, some are moving into babies as young as 6 months old, this IS urgent! If you need another reminder why, go to Forbes and read “The Hideous Truths of Testing Vaccines on Humans”, or watch the videos below.
To get back to the headline question, remember wherever demand forms, a market forms and an industry develops.
It does not access your doctor’s medical file. Here are some excerpts:
In the summer of 2015, Alexandra Franco got a letter in the mail from a company she had never heard of called AcurianHealth. The letter, addressed to Franco personally, invited her to participate in a study of people with psoriasis, a condition that causes dry, itchy patches on the skin.
Franco did not have psoriasis. But the year before, she remembered, she had searched for information about it online, when a friend was dealing with the condition. And a few months prior to getting the letter, she had also turned to the internet with a question about a skin fungus. It was the sort of browsing anyone might do, on the assumption it was private and anonymous.
Now there was a letter, with her name and home address on it, targeting her as a potential skin-disease patient. Acurian is in the business of recruiting people to take part in clinical trials for drug companies. How had it identified her? She had done nothing that would publicly associate her with having a skin condition.
When she Googled the company, she found lots of people who shared her bewilderment, complaining that they had been contacted by Acurian about their various medical conditions. Particularly troubling was a parent who said her young son had received a letter from Acurian accurately identifying his medical condition and soliciting him for a drug trial—the first piece of mail he’d had addressed to him besides birthday cards from family members.
Acurian has attributed its uncanny insights to powerful guesswork, based on sophisticated analysis of public information and “lifestyle data” purchased from data brokers. What may appear intrusive, by the company’s account, is merely testimony to the power of patterns revealed by big data.
“We are now at a point where, based on your credit-card history, and whether you drive an American automobile and several other lifestyle factors, we can get a very, very close bead on whether or not you have the disease state we’re looking at,” Acurian’s senior vice president of operations told the Wall Street Journal in 2013.
Yet there’s some medical information that Acurian doesn’t have to guess about: The company pays Walgreens, which uses a privacy exemption for research, to send recruitment letters to its pharmacy customers on Acurian’s behalf, based on the medications they’re using. Under this arrangement, Acurian notes that it doesn’t access the medical information directly; the customers’ identities remain private until they respond to the invitations.
And that is not the entire story. An investigation by the Special Projects Desk has found that Acurian may also be pursuing people’s medical information more directly, using the services of a startup that advertises its ability to unmask anonymous website visitors. This could allow it harvest the identities of people seeking information about particular conditions online, before they’ve consented to anything.
A letter sent out to a Walgreens customer in Connecticut on Acurian’s behalf. It invited her to visit a generic sounding website for people with pulmonary disease. At the time, she had a prescription from Walgreens for asthma.
If you’re suddenly thinking back on all of the things you’ve browsed for online in your life and feeling horrified, you’re not alone.
AcurianHealth has created dozens and dozens of generic sounding websites for the trials they’re recruiting for: www.trialforCOPD.com,www.studiesforyourarthritis.com, and www.kidsdepressionstudy.com are a few examples of the many websites they own. The sites all feature stock images of people in distress, sometimes include AcurianHealth’s logo, and include promises of up to $1,000 for participating, depending on the study.
Out of view, some of these sites include something else: code from a company called NaviStone—which bills itself as a specialist in matching “anonymous website visitors to postal names and addresses.” So if a person is curious about one of those letters from Walgreens, or follows one of Acurian’s online ads, and visits one of Acurian’s generic disease-specific sites, their identity could be discovered and associated with the relevant condition.
NaviStone says it can send personalized mail to anonymous website visitors with a day or two of their visit.
This tracking function undermines what’s supposedly a formal separation between Walgreens customer data and Acurian’s recruitment. If Walgreens sends out a bunch of letters to customers taking certain medications, and those customers then visit the generic website controlled by Acurian provided in the letter, Acurian can infer its wave of new visitors are taking those medications—and, if NaviStone delivers on its promise to identify visitors, Acurian can see who they are.
Walgreens gives itself permission to use customers’ health information for “research” purposes, which would include clinical trials, in its privacy policy. It’s been working with Acurian since at least 2013, and in 2015, Walgreens announced it was “leveraging” its 100 million customer database to recruit patients directly for five major drug companies.
When asked about its partnership with Acurian, Walgreens spokesperson Scott Goldberg pointed me to a Walgreens FAQ page about clinical trials. It states that Walgreens doesn’t share health information with third parties without permission, but that a third party may “receive your information if you contact the web-site and/or toll-free number in the letter to seek more information about the clinical trial.”
The question is whether users will know that one of Acurian’s websites has received their information—even if they haven’t necessarily agreed to submit it. NaviStone, an Ohio-based business spun out from the marketing firm CohereOne last year, claims to be able to identify between 60 and 70 percent of anonymous visitors to the websites that use its services.
When we contacted the firm last month to ask how it does this, Allen Abbott, NaviStone’s chief operating officer, said by phone that talking about how its technology works is “problematic.”
“A lot of our competitors would love to know how we made it work,” Abbott said. “We have an advantage that we would be silly to reveal.”
We asked whether the company had thought about the privacy implications involved in identifying people visiting a website for sensitive reasons, and whether there were certain customers the company wouldn’t work with.
“Our business is almost entirely e-commerce, helping retailers sell to their customers,” he said. “There was one site that came into our radar that was adult-related material that we decided not to pursue.”
We then described what Acurian does.
“We don’t work with anyone like that,” he said.
We explained that the call was because we’d found NaviStone’s code on AcurianHealth sites.
“It’s possible,” he then said. “We have a lot of customers.”
But Abbott insisted that NaviStone had found a “privacy compliant way” to identify anonymous website visitors—again saying he couldn’t describe it because it was a proprietary technology.
When we analyzed the NaviStone code on Acurian’s sites, we found one way that NaviStone’s technology works: It collects information as soon as it is entered into the text boxes on forms, before the person actually agrees to submit it. When we typed a test email address in the “Join Us” page on Acurian’s site, it was immediately captured and sent to the company’s servers, even if we later chose to close the page without hitting the “Send” button on the form.
In fact, the information was collected before we got to the part of the form that said, “Your privacy is important to us. By selecting this box, you agree to our Privacy Policy and Terms of Use, and agree that we contact you by phone using automated technology or other means using the information you provided above regarding research studies.” – Gizmodo
But that was long ago in terms of technological progress.
However, the methods persist in 2021, an US local tv station reveals that exactly the same scenario occurred in Cincinnati, with the same company at the center of the scandal. Here’s what they’ve just published:
<<Nancy Brashear opened her mail at her Campbell County, Kentucky, home to find an offer to earn money if she joined a COVID-19 vaccine test.
“I got a letter from Acurian Health looking for volunteers for a COVID vaccine study, promising up to $1,200 if you participate or volunteer,” she said.
It looked promising, but Brashear said she started to wonder how they knew she would be a good candidate for a vaccine trial. Did someone with a hospital, doctor’s office or pharmacy sell her health information?
“How do they get my information?” Brashear said. “That really bothers me.”
We called and emailed Acurian Health to find out how they got her name, but did not hear back.
But Brashear found that if you decide to apply, you will then have to give much more medical information to see if you actually qualify. There is no guarantee you will be accepted for a trial, and no guarantee you will earn anything close to $1,200.
“If you go on the website, you have to go through steps to do that, so they are looking for information,” she said.
In the end, she said thanks, but no thanks, wondering if she would be sharing too much medical and personal information with a company she knew little about.
If you want to sign up for a COVID-19 trial, the NIH, National Institutes of Health, is a government site that lists all the authorized vaccine trials going on.
Many of them will pay money, typically a few hundred dollars. However, they may not cover treatment for any side effects.
So be sure to read all the fine print, so you don’t waste your money.>> – WCPO
I don’t know about you, but what I’ve learned so far is:
Pharmafia still does whatever it takes to get what it wants, even primitive hacking as described above.
These methods are still too primitive for the biggest actors in Pharmafia who are well into artificial intelligence and cutting edge technologies
So what are these top cats doing then? I’ve consulted some of my insider sources, put it together with my own digs and, as per usual with these creatures, the most obvious suspicions are also true.
If you’ve been around, you should be aware by now of three tendencies that are one, actually:
1. Big Tech and Big Pharma are merging
2. Healthcare and Big Data are merging
They’re not only after health data, don’t worry, all data helps a sale
3. The above are merging with media and the elected government
What are Google and Facebook selling, in fact? Your data. What for? So you can be best manipulated by different interests, with custom-design ads and policies.
Oracle’s National Electronic Health Records Cloud dates back to the beginnings of the COVID-19 pandemic. In March 2020, a couple of weeks after letting President Trump use his estate near Palm Springs for a $100,000-a-plate golfing fundraiser, Ellison placed a call to the White House. According to a Forbes cover story on Ellison, he “asked Trump if a clearinghouse existed for real-time data about treatment efficacies and outcomes.”
Within a week after the president asked “how much?” and Ellison said, “for free,” the tech titan had brought together a team of Oracle engineers “to build a database and website registering coronavirus cases” and work with the National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA) and other agencies.
The first public acknowledgment of Oracle’s progress came on July 3, 2020, when the NIH’s National Institute for Allergies and Infectious Diseases (NIAID), overseen by Dr. Anthony Fauci, launched the COVID-19 Prevention Trials Network (COVPN), aimed at enrolling thousands of volunteers in large-scale trials for a variety of investigational vaccines and monoclonal antibodies.
Fauci achieved this by merging four existing networks, all researching HIV/AIDS, something they would continue to do. “The network is expected to operate more than 100 clinical trial sites across the United States and internationally,” according to the NIAID press release which also stated “the COVPN website features a customized data collection platform, which Oracle (Redwood Shores, CA) built and donated, to securely identify potential trial participants.”
In August, a paper published by the Johns Hopkins Center for Health Security proposed that the “passive reporting” systems managed by the CDC and FDA ought to be revamped to forge “an active safety surveillance system directed by the CDC that monitors all [COVID-19] vaccine recipients — perhaps by short message service or other electronic mechanisms.”
By September, Operation Warp Speed director Moncef Slaoui was telling the periodical Science: “We’re working super hard on a very active pharmacovigilance system, to make sure that when the vaccines are introduced that we’ll absolutely continue to assess their safety.
In October, Slaoui told the New York Times: “The FDA is proposing that at least 50% of the individuals in the study population have at least two months of follow-up on safety before the vaccines are approved. And secondly, we are working really hard with the FDA and the CDC to make sure we have a very active pharmacovigilance surveillance system to allow us to continue to assess the safety of the vaccines as they are being used in the high risk population.”
And the Wall Street Journal reported in a profile of Slaoui that he’d said “tracking systems will have to be ‘incredibly precise’ to ensure that patients each get two doses of the same vaccine and to monitor them for adverse health effects. Operation Warp Speed has selected the medical-distribution company McKesson and cloud operators Google and Oracle to collect and track vaccine data.”
“This marked the first time that Oracle’s role was revealed to have expanded to include Operation Warp Speed.
Oracle Chairman Ellison’s lucrative government arrangements trace back to the data software pioneer’s origins. In 1975, then in his early thirties, Ellison worked on a project for the electronics company Ampex in the Bay area, building a large terabit memory system for the CIA.
Ellison revealed in 2014 that the CIA not only became his firm’s first customer for a “relational database” two years later, but that he adopted the name from a CIA project called Oracle. “The news about our hot little database traveled around the intelligence community pretty quickly,” Ellison was quoted as saying in the 2003 book, “Softwar.” “In a little over six months’ time we had won several deals — the CIA, Navy Intelligence, Air Force Intelligence and the NSA [National Security Agency].” – Technocracy News
From this industry’s perspective, you enrolling KFC’s Fidelity Club or a vaccine trial is the same technical challenge. One that they keep winning lately.
Remember when the sister of YouTube’s CEO and former wife of Google’s founder Sergey Brin, still a business partner, set up a DNA testing company and then sold the data for $300 million to pharma giant genocidal company GSK?
Oh, it’s all about science and health, sure, but what science and whose health? Because anyone who’s been in touch with reality lately knows a few more things: – Pharmafia invests much more in the science of marketing than in medical sciences – That data often comes from marketing experts such as Google and Facebook – Marketing and propaganda sell and persuade much more efficiently than science when it comes to large masses of people. Or all of them. It’s way easier and cheaper to manipulate the low-IQ majority than to heal it. Especially with these tools Big Tech brought aboard.
What keeps them from finding and manipulating the feeble minds they need for these new atrocities they call “vaccines human trials” and, in fact, are neither vaccines or human, just deranged human abuse experimentation? From what I’ve found out so far, the answer is: nothing. Everything you type on your computer is collected and can be processed to obtain a method to target and determine people to subject their kids to this. It’s probably much easier to sell than some of their other products. This is already a massive industry that often breaks ethical and even legal barriers.
What, you’ve never thought Cambridge Analytica can work for Pharmafia too? Well then remember we’ve passed that, Facebook, Amazon, Microsoft (recording my typing right now) and Alphabet (Google) are not distinguishable from Pharmafia at all. The concept that they wouldn’t take any and all advantage of their new powers and domination is comically delirious. Moderna must be running out of money or love if Google won’t send them a mere 3000 kids, no joke.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
For most of its history, GSK has been headed by the current “US Vaccine Czar“, the head of Operation Warp Speed, Moncef Slaoui, handpicked by Jared Kushner in Trump’s name.
If anyone claims it’s not good, how could’ve they known that in Februaty or in March, when the virus was “novel” and “the data was scarce”?
Can we expect to find more examples of either drug patents that don’t work or hidden medical and science advancements, whatever the case might be here?
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
SILVIEW.media 
